- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BIIB
Recent news which mentions BIIB
10 Biggest Price Target Changes For Thursday
March 03, 2022
From Benzinga
Viatris stock slides 24% as analysts say sale of biosimilars to Indian partner removes key growth driver
February 28, 2022
From MarketWatch
Medicare’s finances and the saga of the Alzheimer’s drug Aduhelm
February 24, 2022
Tickers
BIIB
Tags
BIIB
From MarketWatch
What Investors Can Learn From Biogen's Drug Approval That No One Wants
February 23, 2022
Tickers
BIIB
From Motley Fool
Could Advocacy Groups' Campaign for Aduhelm Benefit Biogen?
February 19, 2022
Tickers
BIIB
From Motley Fool
Stocks That Hit 52-Week Lows On Thursday
February 17, 2022
From Benzinga
Sage Therapeutics - Biogen Partnered Depression Drug Meets Main Goal In Late-stage Study
February 16, 2022
From Benzinga
US Senate Narrowly Votes In Favor Of Biden's Nominee Robert Califf To Lead FDA For Second Time
February 16, 2022
From Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
February 16, 2022
From Benzinga
3 Cutting-Edge, Protein-Degrader Biotech Stocks to Watch
February 16, 2022
From Motley Fool
What to Expect From Biogen's $2.3 Billion Shopping Spree
February 12, 2022
From Motley Fool
2 High-Yield Dividend Stocks That Are Trading Near Their 52-Week Lows
February 10, 2022
From Motley Fool
From Benzinga
From Benzinga
10 Biggest Price Target Changes For Monday
February 07, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
From Benzinga
Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes
February 04, 2022
Tickers
BIIB
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 4, 2022
February 04, 2022
From Benzinga
10 Biggest Price Target Changes For Friday
February 04, 2022
From Benzinga
Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus
February 03, 2022
Tickers
BIIB
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
February 03, 2022
From Benzinga
The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation
February 03, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.